← Leaderboards
Marcus A. Ruscetti
Sloan-Kettering Inst Can Research
$1,704,238
Attributed
$1,704,238
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $437K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,704,238 · 3
By mechanism
R37$820,121 · 1
R00$747,000 · 1
K99$137,117 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Katharine C Hsu$29,362,365
- Joseph Chai-Yuen Sun$17,368,196
- Shakeel Modak$2,048,034
- Corina Amor Vegas$4,067,163
- Scott W Lowe$63,222,126
Others in their field
Other Emerging Leaders on “Mouse Model”
- James Dale Berry · Brigham And Women'S Hospital$25,017,559
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$13,186,126
- Nuno Macarico Da Costa · Allen Institute$11,726,937
- Forrest Christie Collman · Allen Institute$11,726,937
- Jacqueline K White · Jackson Laboratory$11,670,339
- Thomas Dick · Rbhs-New Jersey Medical School$11,611,284
Research focus
Mouse ModelPremalignant CellImmunityMolecularNeoplastic CellPhenotypeGeneticImmune Checkpoint BlockadeMalignant NeoplasmsMediatingCessation Of LifeNatural Killer CellsPathway InteractionsPatient SubsetsAblationCell Cycle ArrestGenetically Engineered MouseImmuneImmunoregulationImmunosuppressionCancer EtiologyCell AgingCellsProduction
Grant awards (6)
Uncovering the heterogenous role of senescence in prostate immune suppression and tumorigenesis$436,965
R37 · FY2025 · CA · contact PI
Uncovering the heterogenous role of senescence in prostate immune suppression and tumorigenesis$383,156
R37 · FY2024 · CA · contact PI
Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumors$249,000
R00 · FY2022 · CA · contact PI
Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumors$249,000
R00 · FY2021 · CA · contact PI
Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumors$249,000
R00 · FY2020 · CA · contact PI
Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumors$137,117
K99 · FY2019 · CA · contact PI